Axiogenesis, a worldwide leading provider of induced pluripotent stem cell (iPS cell) products, has added a vital new service offering, Cardio.Force. This newest service offering includes assay services for iPSC-derived cardiomyocyte functionality and toxicity assessment.
Cardio.Force is based on the Axiogenesis 8 channel Cor.4CE assay device. Currently, 96well versions are in development to further increase the throughput and reduce cost per data point. [Read more…]